Jardiance: the latest SGLT2 for the treatment of type 2 diabetes

E-ISSN： 1931-2253|26|11|30-31

ISSN： 0959-6682

Source： PRESCRIBER, Vol.26, Iss.11, 2015-06, pp. : 30-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

SGLT2 Inhibitors in Diabetes Mellitus Treatment

Reviews on Recent Clinical Trials, Vol. 12, Iss. 1, 2017-01 ,pp. : 8-18

Bentham Science Publishers

Access to resources Recommend Favorite

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo‐Controlled Trial

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 158-169

John Wiley & Sons Inc

Access to resources Recommend Favorite

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 628-635

John Wiley & Sons Inc

Access to resources Recommend Favorite

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

By Musso Giovanni Gambino Roberto Cassader Maurizio Pagano Gianfranco

Annals of Medicine, Vol. 44, Iss. 4, 2012-06 ,pp. : 375-393

Informa Healthcare

Access to resources Recommend Favorite

Xultophy: combination therapy for the treatment of type 2 diabetes

PRESCRIBER, Vol. 26, Iss. 17, 2015-09 ,pp. : 32-34

John Wiley & Sons Inc

Access to resources Recommend Favorite